期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 406, 期 3, 页码 325-332出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(00)00690-7
关键词
apoptosis; eosinophil; fluticasone propionate; budesonide; beclomethasone
Beclomethasone, budesonide, dexamethasone, and fluticasone propionate enhanced human eosinophil apoptosis in a concentration-dependent manner in vitro as assessed by flow cytometric analysis and morphological analysis. The order of potency was fluticasone propionate (EC50 3.7 +/- 1.8 nM) = budesonide (EC50 5.0 +/- 1.7 nM) > beclomethasone (EC50 51 +/- 19 nM) > dexamethasone (EC50 303 +/- 40 nM). Hydrocortisone, prednisolone, and prednisone (up to 1 muM) did not induce any significant increase in eosinophil apoptosis. The apoptosis promoting effects of glucocorticoids on eosinophils were reversed by an antagonist of glucocorticoid receptor mifepristone. The survival-prolonging effect of tumor necrosis factor (TNF)-alpha was reversed by dexamethasone and fluticasone (1 muM). In contrast, fluticasone, and dexamethasone (1 muM) did not reverse the survival-prolonging effects of interleukins-3 and -5 or granulocyte-macrophage colony-stimulating factor (GM-CSF). The results suggest that fluticasone and budesonide induce eosinophil apoptosis at clinically achievable drug concentrations via an effect on glucocorticoid receptor. (C) 2000 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据